Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
Proprietary T-Bolt™ technology dramatically broadens the benefits of immunotherapy by targeting the entire universe of cancer antigens …